The team in Edinburgh at Edinburg Cancer Centre has just published a new article regarding their work with the old Raypilot device and also with the Raypilot catheter solution.
The conclusion is that real time motion monitoring of the prostate gland has been shown to be possible with both of the implantable devices reported in this preliminary study and has proven to be beneficial in the accurate delivery of dose during prostate SBRT.
The pattern of prostate shift and the acute toxicity observed using these devices is in line with previous studies. Both devices have been well tolerated by patients. Being able to insert the transmitter during a normal catheterisation procedure, eliminating a surgical appointment, has not only proven to be beneficial to the scheduling of treatment sessions but has allowed RTTs to be involved throughout the whole pathway. Reassuringly monitoring prostatic motion, via the urethra, has not proven to be detrimental to the dose delivered to the bladder and rectum when compared to the original device. Acceptable, acute, patient reported toxicities are reported for both groups.
At the time of treatment delivery having the ability to control bladder volume, by way of the catheter, has helped with a more efficient workflow.
Read full article here